Xeris Biopharma (NASDAQ:XERS) Trading 4.9% Higher - Should You Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report)'s share price shot up 4.9% during mid-day trading on Tuesday . The company traded as high as $4.33 and last traded at $4.37. 114,670 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 1,850,799 shares. The stock had previously closed at $4.16.

Analyst Ratings Changes

Several research analysts have commented on XERS shares. Piper Sandler reissued a "neutral" rating and set a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Jefferies Financial Group reaffirmed a "buy" rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Craig Hallum increased their price target on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research note on Friday, March 7th. Finally, Leerink Partners upped their target price on Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $6.10.

Xeris Biopharma Price Performance

The company has a market cap of $632.69 million, a price-to-earnings ratio of -9.13 and a beta of 1.37. The business's fifty day moving average price is $4.44 and its 200 day moving average price is $3.70.

Insider Buying and Selling

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This represents a 2.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.56% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of XERS. NewEdge Advisors LLC bought a new position in Xeris Biopharma during the fourth quarter worth $34,000. R Squared Ltd bought a new position in shares of Xeris Biopharma in the 4th quarter worth about $42,000. Cibc World Markets Corp acquired a new position in shares of Xeris Biopharma in the 4th quarter valued at about $44,000. Raymond James Financial Inc. bought a new stake in shares of Xeris Biopharma during the 4th quarter valued at about $45,000. Finally, Two Sigma Advisers LP acquired a new stake in Xeris Biopharma during the fourth quarter worth approximately $47,000. Institutional investors and hedge funds own 42.75% of the company's stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.